Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone IV injection Clear all
Completed Phase 3 Interventional Results available

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

NCT00283062
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 25, 2026, 4:59 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup

NCT03705273
View directory record Official record
Conditions
Asthma, Croup
Interventions
Dexamethasone IV for PO, Dexamethasone crushed tablets
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Year to 7 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone for Post-cesarean Delivery Pain

NCT01812057
View directory record Official record
Conditions
Pain, Postoperative, Postoperative Nausea and Vomiting
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 25, 2026, 4:59 PM EDT
Withdrawn Phase 2 Interventional

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

NCT05293509
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Fludarabine, Dexamethasone, Cyclophosphamide, Bortezomib, Rituximab, Busulfan, Cyclophosphamide (Cy), Tacrolimus (or cyclosporine), Mycophenolate mofetil (MMF), Rabbit ATG
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 25, 2026, 4:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

NCT05451771
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

NCT01319981
View directory record Official record
Conditions
Leukemia
Interventions
Rituximab, Imatinib, Cyclophosphamide, Doxorubicin, Mesna, VSLI, Solu-Medrol, Methotrexate, Ara-C, G-CSF, Pegfilgrastim, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Sep 25, 2026, 4:59 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

NCT05852717
View directory record Official record
Conditions
Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
Interventions
AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab
Procedure · Drug
Lead sponsor
Dipenkumar Modi
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Indianapolis, Indiana • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Bevacizumab in Combination With Pemetrexed

NCT00227019
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
Interventions
Bevacizumab, Pemetrexed, Vitamin B12, Folate, Dexamethasone
Drug
Lead sponsor
Heather Wakelee
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
4
States / cities
Stanford, California • Lebanon, New Hampshire • Voorhees Township, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 25, 2026, 4:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Not yet recruiting Phase 4 Interventional

Aprepitant to Improve Same Day Discharge for TKA

NCT07639723
View directory record Official record
Conditions
PONV
Interventions
Aprepitant Injection, Ondansetron (Zofran), Dexamethasone, Placebo
Drug · Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 90 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT04302324
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Daratumumab SC, Clarithromycin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

NCT00437229
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 25, 2026, 4:59 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT05096663
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Cobalamin, Dexamethasone, Docetaxel, Folic Acid, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab
Dietary Supplement · Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
350
States / cities
Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Results available

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

NCT02335983
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
59
States / cities
Bakersfield, California • Burbank, California • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 25, 2026, 4:59 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

NCT03571321
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Interventions
Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

NCT04054193
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

NCT03023878
View directory record Official record
Conditions
High-risk Diffuse Large B-Cell Lymphoma
Interventions
Blinatumomab, Investigator's Choice Chemotherapy, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Chicago, Illinois • Maywood, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

NCT00507416
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Melphalan, Prednisone, Thalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
234
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Results available

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

NCT01980589
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Encinitas, California • West Hollywood, California • Whittier, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 25, 2026, 4:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Selinexor and Backbone Treatments of Multiple Myeloma Patients

NCT02343042
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

NCT00989781
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
3-D Ultrasound, recombinant human chorionic gonadotropin, Recombinant human follicle stimulating hormone, Adrenocorticotropin, Dexamethasone, Glucose
Radiation · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone and Pain Following Total Knee Arthroplasty

NCT02271698
View directory record Official record
Conditions
Acute Pain, Chronic Pain
Interventions
Dexamethasone, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 25, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT02128230
View directory record Official record
Conditions
Multiple Myeloma
Interventions
myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
Device · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 25, 2026, 4:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

NCT07479979
View directory record Official record
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Selinexor, Carfilzomib, Isatuximab, Isatuximab SC Wearable Injection System, Dexamethasone
Drug · Device
Lead sponsor
Natalie Callander
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 4:59 PM EDT